Real-World, Long-Term Quality of Life Following Therapeutic OnabotulinumtoxinA Treatment

Canadian Journal of Neurological Sciences

Volumn 43, Issue 5, 2016, Pages 687-696

  Jog, Mandar ^a   Wein, Theodore ^b   Bhogal, Meetu ^c   Dhani, Sonja ^c   Miller, Robert ^d   Ismail, Farooq ^e   Beauchamp, Richard ^f   Trentin, Grace ^c  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c ALLERGAN PLC   (United States)

^d DALHOUSIE UNIVERSITY   (Canada)

^e West Park Healthcare Centre   (Canada)

^f CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

Cerebral Palsy; Clinical Trials; Movement Disorders; Quality Of Life; Spasticity

Indexed keywords

BOTULINUM TOXIN A; ACETYLCHOLINE RELEASE INHIBITOR;

ADULT; AGED; ARTICLE; BLEPHAROSPASM; CAUCASIAN; CEREBRAL PALSY; CERVICAL DYSTONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; FEMALE; FOLLOW UP; HEADACHE; HEMIFACIAL SPASM; HUMAN; HYPERHIDROSIS; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MUSCLE TIGHTNESS; MUSCLE WEAKNESS; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PHASE 4 CLINICAL TRIAL; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SHORT FORM 12; SHORT FORM 6D; SPASTICITY; SWELLING; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ADOLESCENT; CANADA; CLINICAL TRIAL; COHORT ANALYSIS; HEALTH SURVEY; MUSCLE SPASTICITY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TIME FACTOR; TORTICOLLIS; VERY ELDERLY; YOUNG ADULT;

ACETYLCHOLINE RELEASE INHIBITORS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLEPHAROSPASM; BOTULINUM TOXINS, TYPE A; CANADA; CEREBRAL PALSY; COHORT STUDIES; FEMALE; HEALTH SURVEYS; HEMIFACIAL SPASM; HUMANS; HYPERHIDROSIS; MALE; MIDDLE AGED; MUSCLE SPASTICITY; OUTCOME ASSESSMENT (HEALTH CARE); PRAGMATIC CLINICAL TRIALS AS TOPIC; QUALITY OF LIFE; TIME FACTORS; TORTICOLLIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84988926165     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/cjn.2016.262     Document Type: Article

References (28)

1. Allergan Inc. Product Monograph. BOTOX (onabotulinumtoxinA). 2014. Markham, ON.
2. Jankovic J, Esquenazi A, Fehlings D, Freitag F, Lang AM, Naumann M. Evidence-based review of patient-reported outcomes with botulinum toxin type A. Clin Neuropharmacol. 2004;27:234-44.
3. Centers for Disease Control and Prevention. Health-related quality of life (HRQOL). National Center for Chronic Disease Prevention and Health Promotion, Division of Population Health. 2011.
4. Armstrong D, Caldwell D. Origins of the concept of quality of life in health care: a rhetorical solution to a political problem. Social Theory &Health. 2004;2:361-71.
5. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA. 1995;273:59-65.
6. Grima DT, Torrance GW, Francis G, Rice G, Rosner AJ, Lafortune L. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler. 2000;6:91-8.
7. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med. 1993;118:622-9.
8. Kopec JA, Willison KD. A comparative review of four preferenceweighted measures of health-related quality of life. J Clin Epidemiol. 2003;56:317-25.
9. Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96:5-21.
10. Parker L, Moran GM, Roberts LM, Calvert M, McCahon D. The burden of common chronic disease on health-related quality of life in an elderly community-dwelling population in the UK. Fam Pract. 2014;31:557-63.
11. Maruish ME. User's manual for the SF-12v2 Health Survey, 3rd ed. Lincoln, RI: Quality Metric Incorporated, 2012.
12. Ware J Jr., Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220-33.
13. Haacke C, Althaus A, Spottke A, Siebert U, Back T, Dodel R. Long-term outcome after stroke: evaluating health-related quality of life using utility measurements. Stroke. 2006;37:193-8.
14. Hopman WM, Berger C, Joseph L, et al. Stability of normative data for the SF-36: results of a three-year prospective study in middleaged Canadians. Can J Public Health. 2004;95:387-91.
15. Hopman WM, Berger C, Joseph L, et al. The natural progression of health-related quality of life: results of a five-year prospective study of SF-36 scores in a normative population. Qual Life Res. 2006;15:527-36.
16. Orpana HM, Ross N, Feeny D, McFarland B, Bernier J, Kaplan M. The natural history of health-related quality of life: a 10-year cohort study. Health Rep. 2009;20:29-35.
17. Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes. 2003;1:54.
18. Joore M, Brunenberg D, Nelemans P, et al. The impact of differences in EQ-5D and SF-6D utility scores on the acceptability of costutility ratios: results across five trial-based cost-utility studies. Value Health. 2010;13:222-9.
19. Hsiung GY, Das SK, Ranawaya R, Lafontaine AL, Suchowersky O. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord. 2002;17:1288-93.
20. Mejia NI, Vuong KD, Jankovic J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord. 2005;20:592-7.
21. Ramirez-Castaneda J, Jankovic J. Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up. Toxicon. 2014;90:344-8.
22. McKevitt C, Fudge N, Redfern J, et al. Self-reported long-term needs after stroke. Stroke. 2011;42:1398-403.
23. Wolfe CD, Crichton SL, Heuschmann PU, et al. Estimates of outcomes up to ten years after stroke: analysis from the prospective South London Stroke Register. PLoS Med. 2011;8:e1001033.
24. Ababneh OH, Cetinkaya A, Kulwin DR. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm. Clin Experiment Ophthalmol. 2014; 42:254-61.
25. Brashear A. The safety and tolerability of botulinum toxins for the treatment of cervical dystonia. Expert Opin Drug Saf. 2005;4:241-9.
26. Defazio G, Abbruzzese G, Girlanda P, et al. Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study. Arch Neurol. 2002;59:418-20.
27. Rosales RL, Chua-Yap AS. Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity. J Neural Transm. 2008;115: 617-23.
28. Snyder CF, Aaronson NK, Choucair AK, et al. Implementing patient-reported outcomes assessment in clinical practice: a review of the options and considerations. Qual Life Res. 2012;21:1305-14.